Biotech Stock Mailbag: Amarin, MannKind, Palatin
He probably thinks earlier than that.. - Schnuz May 22, 2013 Nope. I mean FDA will reject Vascepa for the "Anchor" mixed dyslipidemia indication.
Amarin Stays Rangebound, Prescriptions Stagnate
Amarin Corporation has been struggling a lot lately as retail channel prescription data for its EPA capsule Vascepa imply that the drug is starting to slow down its momentum in the MARINE indication .
Wed May 22, 2013
These 2 Patents Could Mean Everything Or Nothing
Interestingly enough, the two biotech stories that I watch both had patent approval news today.
Mon May 20, 2013
Vascepa Data Should Make Amarin Longs Worried
Amarin had been trading bullish on the heels of their quarterly conference call two weeks ago where they reported a continued increase in Vascepa sales and $2.3 million in recognized Vascepa revenues.
StockCall Pre-Market Review on AMRN, ARAY, ATRS, and ANTH
The healthcare sector has been facing significant challenges over the last few years.
Tue May 14, 2013
Biogen Idec Inc. (NASDAQ:BIIB), Amarin Corporation plc (NASDAQ:AMRN), ...
Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Biogen Idec Inc.
Mon May 13, 2013
Amarin Corporation plc (ADR) (AMRN) News: A Big 'Outperform,' Vascepa TRx Info & An Omega-3 Test
Amarin Co. plc Receives "Outperform" Rating from Leerink Swann Leerink Swann reissued their outperform rating on shares of Amarin Corporation plc in a research report released on Thursday morning, Stock Ratings Network reports.
Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground
Last week was quite decent for Amarin Corporation investors, who saw a 6% rally last Friday in reaction to the company's Q1 2013 financial results.
Sat May 11, 2013
Omthera Pharmaceuticals Receives New Coverage from Analysts at Piper Jaffray
The analysts wrote, "Omthera is developing Epanova, an ultra-pure mixture of the omega-3 fish oils EPA and DHA.
Thu May 09, 2013
Amarin Corporation plc (ADR) (AMRN): The 7 Most Committed Hedgies
AMRN investors should be aware of a decrease in support from the world's most elite money managers of late.
Amarin Corporation CEO Discusses Q1 2013 Results - Earnings Call Transcript
Welcome to Amarin Corporations Conference Call to discuss its first quarter 2013 financial and operating results.
Another Negative Fish Oil Study Adds To Amarin's Marketing Challenges
Nothing has come easy for Amarin . This manufacturer of the ultra-pure fish oil treatment Vascepa has garnered a devoted following of investors who believe that this is not just the next Lovaza acquired in 2007 for $1.7 billion by buying Reliant Pharmaceuticals), but even more.
Wed May 08, 2013
Amarin managers to discuss finances
Senior managers of Amarin Corp. plc, a biotech company with research headquarters in Groton, will discuss the company's first-quarter financial results at 4:30 p.m. Thursday during a conference call.
Mon May 06, 2013
Can Amarin Make Me A Believer This Thursday?
Amarin longs don't really like me. The same kind of way that Carl Icahn and Bill Ackman "don't really" like each other.
Tue Apr 30, 2013
Amarin: The Bull Argument
The bull argument for Amarin's Vascepa is simple: it works better than Lovaza, it doesn't have the negative aspects, it doesn't have an atrial fibrillation warning, it is applying for approval to be marketed to a ten times larger patient population, and the combo drug looks to be the best treatment for hyperlipidemia ever created, per the patent ... (more)
Mon Apr 29, 2013
Amarin's Performance Issues: Here To Stay?
Amarin Corporation is one of the most controversial and debated stocks in recent memory.